Published in Histol Histopathol on April 01, 2000
Putative DNA quadruplex formation within the human c-kit oncogene. J Am Chem Soc (2005) 3.28
C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia (2008) 1.11
Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo. Clin Cancer Res (2013) 0.94
The picture of the prostatic lymphokine network is becoming increasingly complex. Rev Urol (2002) 0.91
Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts. Biomed Res Int (2013) 0.87
Mast cells and human hepatocellular carcinoma. World J Gastroenterol (2003) 0.83
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer. Int J Nanomedicine (2016) 0.81
Expression of c-kit protein in cancer vs. normal breast tissue. Contemp Oncol (Pozn) (2012) 0.77
Carcinosarcoma of the prostate: two cases with distinctive morphologic and immunohistochemical findings. Virchows Arch (2005) 0.76
Human Stromal Cells in the Peripheral Zone of the Prostate Promote Tumorigenesis of Prostatic Cancer Stem Cells through Up-regulation of C-Kit Expression. J Cancer (2015) 0.75
Poorly differentiated carcinoma of the rectum with aberrant immunophenotype: a case report. World J Gastroenterol (2007) 0.75
Normal peripheral prostate stromal cells stimulate prostate cancer development: roles of c-kit signal. Am J Transl Res (2015) 0.75
Screening of candidate G-quadruplex ligands for the human c-KIT promotorial region and their effects in multiple in-vitro models. Oncotarget (2016) 0.75
KIT protein expression and mutational status of KIT gene in pituitary adenomas. Virchows Arch (2012) 0.75
Pten is essential for embryonic development and tumour suppression. Nat Genet (1998) 13.41
Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 11.41
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A (1999) 7.88
Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science (2001) 7.13
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet (2001) 5.92
Peripheral Nerves in Chronic Atrophic Arthritis. Am J Pathol (1942) 5.21
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (2001) 4.99
Lesions of Skeletal Muscles in Rheumatoid Arthritis: Nodular Polymyositis. Am J Pathol (1946) 4.86
Impaired Fas response and autoimmunity in Pten+/- mice. Science (1999) 4.25
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Role of PML in cell growth and the retinoic acid pathway. Science (1998) 3.82
Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys (1998) 3.82
Antibacterial nature of prostatic fluid. Nature (1968) 3.68
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Inhibition of phagocytosis of complement C3- or immunoglobulin G-coated particles and of C3bi binding by monoclonal antibodies to a monocyte-granulocyte membrane glycoprotein (Mol). J Clin Invest (1983) 3.23
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res (1994) 2.98
Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med (1978) 2.92
Classification of benign diseases associated with prostatic pain: prostatitis or prostatodynia? J Urol (1978) 2.74
Genetic alterations in bladder cancer. Lancet (1993) 2.73
Ku70 is required for DNA repair but not for T cell antigen receptor gene recombination In vivo. J Exp Med (1997) 2.71
Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst (1995) 2.70
Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell (1996) 2.66
NODULAR POLYMYOSITIS IN RHEUMATOID ARTHRITIS. Science (1945) 2.59
Mixed connective tissue disease: to be or not to be? Arthritis Rheum (1998) 2.58
Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. Proc Natl Acad Sci U S A (1999) 2.58
The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell (1991) 2.56
Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res (1999) 2.55
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene (1990) 2.50
Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res (2001) 2.48
Deficiency of a granulocyte-membrane glycoprotein (gp150) in a boy with recurrent bacterial infections. N Engl J Med (1982) 2.47
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med (1988) 2.40
Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst (1998) 2.39
Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) (2006) 2.36
Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest (1995) 2.33
Growth of a pure population of mouse mast cells in vitro with conditioned medium derived from concanavalin A-stimulated splenocytes. Proc Natl Acad Sci U S A (1981) 2.33
Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst (1995) 2.25
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 2.22
Identification of a site on 23S ribosomal RNA located at the peptidyl transferase center. Proc Natl Acad Sci U S A (1984) 2.22
Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med (1997) 2.21
Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol (1998) 2.21
Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest (2001) 2.20
Ku70: a candidate tumor suppressor gene for murine T cell lymphoma. Mol Cell (1998) 2.18
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res (1993) 2.14
The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol (1997) 2.13
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer (1997) 2.13
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol (2001) 2.06
Expression of the prostate-specific membrane antigen. Cancer Res (1994) 2.06
Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med (1974) 2.05
HIV antigen in the brains of patients with the AIDS dementia complex. Ann Neurol (1987) 2.04
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 2.02
The TNM classification of prostate cancer. Prostate Suppl (1992) 1.96
Adult urological sarcoma. J Urol (1992) 1.94
Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol (1997) 1.93
The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol (1992) 1.91
Gene amplification in gastric and esophageal adenocarcinomas. Cancer Res (1990) 1.90
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res (1996) 1.88
Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol (1998) 1.88
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res (2000) 1.87
Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology (1985) 1.86
Expression of ras proto-oncogene proteins in normal human tissues. Oncogene (1987) 1.86
Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem (2000) 1.85
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res (2000) 1.85
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res (1996) 1.82
Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature (1998) 1.82
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst (1992) 1.81
Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med (1986) 1.79
Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes (1993) 1.78
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol (1994) 1.78
Development and progression of clubbing and scarring in children with recurrent urinary tract infections. Radiology (1974) 1.78
Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol (1991) 1.78
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis (2005) 1.77
The reliability of analysis of intraoperative frozen sections for identifying active infection during revision hip or knee arthroplasty. J Bone Joint Surg Am (1996) 1.77
Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res (2000) 1.75
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (1999) 1.74
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol (1995) 1.71
Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract. Cancer Res (1998) 1.68
Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.67
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65
Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol (1997) 1.65
Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med (2001) 1.63
Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst (1999) 1.63
Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer (1997) 1.62